SCIENTIFIC RESULTS

PN6047 CONCISELY

Therapeutic focus » Scientific Results

Neuropathic pain therapy point by point

OUR LEAD MOLECULE PN6047 has the ability to become a medicine for the treatment of chronic pain. This is underpinned by the following:

  • PN6047 is a novel fully patented molecule without any significant toxic effects in preclinical testing. PN6047 can be cost effectively synthesized
  • PN6047 is highly selective for the delta opioid receptor and does not interact with other receptors, transporters or enzymes studied
  • PN6047 preferentially signals via Gi proteins compared with arrestin proteins
  • PN6047 has high potency and efficacy in reducing neuropathic pain in various animal models
  • PN6047 lacks unwanted morphine-like side-effects, such as analgesic tolerance, drug abuse potential and respiratory depression
  • PN6047 has an excellent preclinical safety profile lacking CVS/GIT interactions and seizure induction
  • PN6047 shows no histopathological  effects following long-term multiple high dose administration.

THUS, PN6047 can be the drug of choice to combat neuropathic pain and other conditions involving sensory hypersensitivity such as chronic cough and itch.

PN6047 versus conventional

The advantages of PN6047, versus current neuropathic pain medicines are potentially substantial.

vs Conventional Opioids:  
Better efficacy in sensory hypersensitivity disorders; no μ-opioids receptor side effects; no analgesic  tolerance; no abuse potential.

vs Gabapentin:
No dose adjustment in renal insufficiency patients; no abuse potential; no cytochrome enzyme inhibition so less drug interactions.

vs Amitriptyline:
No cardiovascular complications; lower metabolite exposure; no dose adjustment in hepatic insufficiency patients; no significant food or drug interactions.

Latest news

View all
January 30, 2024

NIDA funds studies

The US National Institute of Drug Abuse (NIDA) has funded a project investigating the drug candidate PN6047, a novel and highly selective Delta Opioid Receptor Agonist (DORA), represents a unique approach to addressing this medical challenge.

Read more
January 30, 2024

A new perspective in pain management and opioid withdrawal relief

We are proud to share an article in Dagens Industri about our groundbreaking work with PN6047. Our promising drug candidate not only has the potential to revolutionise pain relief but has also caught the attention of the National Institute on Drug Abuse (NIDA) for its role in opioid withdrawal treatment. Per von Mentzer, our CEO, states: "Our work with PN6047 could open new paths in pain relief. Particularly in neuropathic pain, our research could lead to new insights and novel treatment approaches in various clinical areas." PN6047, a selective DORA, offers a new perspective on both pain management and opioid withdrawal treatment. The results from the Phase I study show promising safety and tolerance, paving the way for further studies on its effects on opioid withdrawal syndrome.

Read more
October 18, 2023

Phase IIa studies with WCT

Following the successful completion of our phase I study, we are pleased to announce our collaboration with WCT, Worldwide Clinical Trials, as the phase IIa study of our drug candidate PN6047. This partnership underscores our commitment to developing solutions for neuropathic pain. In the upcoming phase IIa study, PharmNovo will investigate the safety, tolerability, pharmacokinetics, and efficacy of their drug candidate PN6047 for individuals affected by neuropathic pain and experiencing Mechanical Allodynia. This distressing symptom, caused by nerve injury, often disrupts daily life and sleep. PN6047 offers a targeted approach to alleviate this condition, aiming to improve the overall pain experience. Insights on its efficacy will aid in designing subsequent phase IIb/III studies.

Read more
October 18, 2023

Meet Jesper Kjerulff, Chief operations officer and Global project lead

In the pharmaceutical development arena, experts like Jesper Kjerulff stand out. As Global project lead and Chief operations officer (COO) of PharmNovo, Jesper Kjerulff is instrumental in propelling the company's groundbreaking project, PN6047, and advancing the field of neuropathic pain management.

Read more